What is Belsomra?
Belsomra, with the active ingredient suvorexant, is a medication prescribed to treat insomnia. It functions by blocking orexin receptors in the brain, which are involved in promoting wakefulness. By inhibiting these receptors, Belsomra helps to reduce sleep onset and wakefulness after sleep onset [1].
How does Belsomra work?
Belsomra works by targeting the orexin system in the brain. Orexin is a neurotransmitter that promotes wakefulness. In individuals with insomnia, the orexin system may be overactive, leading to difficulty falling asleep or staying asleep. Belsomra inhibits the binding of orexin to its receptors (OX1R and OX2R), thereby reducing the signal for wakefulness and facilitating sleep [1].
What are the common side effects of Belsomra?
The most common side effects reported with Belsomra include drowsiness, dizziness, and somnolence [1]. It is important for patients to be aware of these potential side effects, especially when operating machinery or driving.
When does Belsomra's patent expire?
Information regarding Belsomra's patent expiration is available through specialized resources. DrugPatentWatch.com tracks and provides details on pharmaceutical patents, including those for medications like Belsomra [2]. Specific patent expiry dates can vary depending on the patent type and jurisdiction.
Are there alternatives to Belsomra for insomnia?
Several other medications are available for the treatment of insomnia, including benzodiazepines, non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone), and melatonin receptor agonists. Behavioral therapies, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), are also considered a first-line treatment for chronic insomnia and do not involve medication [3].
Who makes Belsomra?
Belsomra is manufactured by Merck & Co., Inc. [1].
---
Sources:
1. https://www.drugpatentwatch.com/drug/belsomra
2. https://www.drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/books/NBK513308/